



Gp|1646

Patent Docket No. P1834

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 12 2001

Technology Center 2600

#5
M.Q.)
4/16/01

In re Application of
Ellen H. Filvaroff
Serial No.: 09/685,823
Filed: October 9, 2000
For: *Use of IL-17 and LIF Antagonists for the Treatment of Cartilagenous Disorders*


Group Art Unit: 1646

Examiner: D. Jiang

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Sequence, Commissioner of Patents and Trademarks, Washington, DC 20231 on

April 4, 2001



Glory L. Tabuena

RESPONSE TO RESTRICTION

RECEIVED

APR 10 2001

Technology Center 2600

Commissioner of Patents and Trademarks

Washington, DC 20231


Sir:

In response to Examiner Jiang's Restriction dated March 26, 2001, Applicant hereby elects, without traverse, Group 1, drawn to a method of treating or preventing cartilage damage with an antagonist to IL-17. With respect to the species election further defining the cartilage agent, Applicant hereby elects the IL-1 receptor antagonist (IL-1ra) species of the subgenus "catabolism antagonist" detailed as a Markush group in Claim 18.

The Commissioner is authorized to charge any additional fees due in connection with the filing of this document to our Deposit Account No. 07-0630. A duplicate copy of this transmittal is enclosed.

Respectfully submitted,

GENENTECH, INC.

By: 
Craig G. Svoboda
Reg. No. 39,044
Telephone: (650) 225-1489

Date: April 4, 2001



09157

PATENT TRADEMARK OFFICE